Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)

Date

21 Oct 2023

Session

Poster session 20

Topics

Laboratory Diagnostics;  Pathology/Molecular Biology;  Targeted Therapy;  Molecular Oncology;  Genetic and Genomic Testing

Tumour Site

Non-Small Cell Lung Cancer

Presenters

George Simon

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

G. Simon1, A. Berry2, B. Bapat3, J. Law4, C. Sweetnam4, H. Mohammed4, A. McBratney4, M. Izano4, M. Scannell Bryan4, S. Spencer5, D. Hostin3, B. Schroeder3, P.G. Febbo6

Author affiliations

  • 1 Medical, Moffitt Cancer Center, 33612 - Tampa/US
  • 2 Svp Biomarker Data And Lab Medicine, Syapse, 94107 - San Francisco/US
  • 3 Global Market Access, Illumina, Inc., 92122 - San Diego/US
  • 4 Heor, Syapse, 94107 - San Francisco/US
  • 5 Heor, Illumina, Inc., 9212 - Denver/US
  • 6 Medical, Illumina, Inc., 92122 - San Diego/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1422P

Background

Advances in therapies for patients with NSCLC require personalizing treatment based on patients' tumor genetic profiles to improve outcomes. Approaches to evaluate tumor biomarkers include a range of testing from single gene/small panel to CGP which includes hundreds of genes and signatures like TMB and MSI. This study compared actionable biomarker detection, targeted therapy receipt, and clinical outcomes in patients with aNSCLC tested with CGP vs small panels (SP).

Methods

This is a retrospective study of adult patients in the US community setting diagnosed with aNSCLC between 1/1/2015 and 12/31/2020. Patients were followed from aNSCLC diagnosis (index) until the earliest of death or study-end and (9/30/2021) categorized based on the most comprehensive testing during follow-up as SP (≤52 genes) or CGP (>52 genes). Biomarker actionability was defined by OncoKB1: FDA recognized (Level 1), standard of care (Level 2), standard of care predictive of resistance (Level R1). Likelihood of receipt of matched therapy was assessed using logistic regression; Kaplan-Meier and Cox proportional hazards models were used to assess real- world overall survival (rwOS).

Results

Among 3,884 patients (median age 68y, 50% female, 73% Non-Hispanic White), 20% received CGP and 80% SP as the most comprehensive test. The proportion of patients with ≥1 actionable biomarker was significantly higher in CGP than SP (32% vs 14%; p<0.001). Of patients with actionable biomarkers, 43%(CGP) and 38% (SP) received matched therapies (p=0.20). Among treated patients: (1) CGP prior to 1st line treatment was associated with higher likelihood of receiving matched therapy (OR=3.21[95%CI: 1.98, 5.19]); (2) patients receiving CGP testing during follow-up had greater median rwOS (22 months[95%CI:18-25] vs. 15 months[95%CI:14-16]) and reduced risk of mortality (HR: 0.80[95% CI: 0.72, 0.89]) compared to SP.

Conclusions

Patients who received CGP had improved use of matched therapies and greater rwOS compared to SP. . Broader adoption of CGP may improve detection of actionable biomarkers, facilitating appropriate timely delivery of precision therapies resulting in better outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Syapse Inc.

Funding

Illumina, Inc.

Disclosure

G. Simon: Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, AstraZeneca, Dava Oncology, Merck, Reflexion, Genprex, Syapse , IDP Pharma, Onc. AI ; Financial Interests, Personal, Invited Speaker: Celegene, AstraZeneca, OncoLive, Nexus Oncology, PER Oncology; Financial Interests, Personal, Research Grant: Merck, BI. A. Berry: Financial Interests, Institutional, Stocks/Shares: Syapse; Financial Interests, Institutional, Full or part-time Employment: Syapse. B. Bapat: Financial Interests, Institutional, Stocks/Shares: Illumina. J. Law, C. Sweetnam, H. Mohammed, A. McBratney, M. Izano, M. Scannell Bryan: Financial Interests, Institutional, Full or part-time Employment: Syapse. S. Spencer, D. Hostin, B. Schroeder, P.G. Febbo: Financial Interests, Institutional, Full or part-time Employment: Illumina.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.